Bacil Pharma Ltd

Bacil Pharma Limited — Trading window closes from 1st October, 2026 till 48 hours after the conclusion of the Meeting of the Board of Directors to be held for the purpose of considering the Un-audited Financial Results for the quarter and half year ended 30th September, 2026.

AGM details

• AGM held on 23 September 2026 at 3:00 PM IST via VC/OAVM.

Scrutinizer report

• Scrutinizer report consolidated for remote e-voting and E-voting during AGM.

AGM Details

• AGM held Sept 23, 2026 at 3:00 PM IST via VC/OAVM; attendance 66 members.

Resolutions Proposed

• Ordinary: Adoption of the audited financial statements for FY2026.
• Ordinary: Re-appointment of director retiring by rotation (Chaitali Kalpataru Shah).
• Special: Change in designation to Managing Director for Chaitali Kalpataru Shah.
• Special: Re-appointment of Omprakash Sonar as Non-Executive Independent Director.
• Special: Re-appointment of Vivek Yadav as Non-Executive Independent Director.
• Special: Appointment of Sarang Shivajirao Chavan & Associates as Statutory Auditors; remuneration to be fixed.
• Ordinary: Increase in Authorized Share Capital and MOA alteration.
• Special: Re-appointment of Mahesh Singh as Non-Executive Independent Director.
• Special: Re-appointment of Anil Singh as Non-Executive Non-Independent Director.

Voting Status

• Voting results will be published on the company's site and with the stock exchange within 48 hours.

Directors & Auditors

• Change in designation: Chaitali Kalpataru Shah becomes Managing Director.
• Re-appointment: Omprakash Sonar as Non-Executive Independent Director.
• Re-appointment: Vivek Yadav as Non-Executive Independent Director.
• Re-appointment: Mahesh Singh as Non-Executive Independent Director.
• Re-appointment: Anil Singh as Non-Executive Non-Independent Director.
• Appointment: Sarang Shivajirao Chavan & Associates as Statutory Auditors; remuneration to be fixed.
• Capital: Increase in Authorised Share Capital and MOA alteration.

Financial snapshot

• Total revenue for FY2025-26: ₹123.52 lakh.
• Core operating revenue nil; income from other income drove performance.
• Profit before tax: ₹99.02 lakh.
• OCI impact: negative ₹217.43 lakh.
• Profit after tax and OCI: ₹-61.88 lakh.
• Earnings per share: ₹1.11.
• Total assets: ₹2,739.27 lakh; cash ₹56.85 lakh at year-end.
• Cash flow: operating ₹71.16 lakh; investing ₹-238.16 lakh; financing ₹-61.88 lakh.
• Dividend: not proposed.

Capital structure & shareholding

• Authorized capital increased to ₹70 crore; MOA amended.
• Paid-up equity share capital: ₹14.35 crore (1,43,53,000 shares).
• Dematerialisation level: 85.54%.
• Shareholders: Public 7,226 holders; Promoters 0; all shares with public.

Board, governance & key appointments

• Chaitali Kalpataru Shah appointed Executive Director & CFO from 16 July 2025.
• Resigned: Prakash Bhoorchand Shah (22 July 2025).
• Resigned: Jayesh Ramchandra Patil, CFO (10 July 2025).
• Resigned: Bhavana Tak, Company Secretary (1 December 2025).
• Dikshant Singh Panwar appointed Company Secretary (19 December 2025).
• Post-year: Omprakash Sonar & Vivek Yadav appointed 30 June 2026 as NEDs.
• Dinesh Notiyal & Avani Godhaniya resigned 9 July 2026.
• Mahesh Singh appointed 25 August 2026; Anil Singh appointed 25 August 2026.

Auditors, secretarial & compliance

• Laxmikant Kabra & Co LLP resigned August 12, 2025.
• Sarang Shivajirao Chavan & Associates appointed as statutory auditors from Sept 29, 2025.
• Secretarial auditor: Ramesh Chandra Bagdi & Associates.
• Shareholding pattern submission delay noted by SEBI LODR; not material to operations.

Business developments & strategy

• Investment in CNX Corporation Ltd via share swap.
• Strategic focus on healthcare solutions; exploring new business lines.
• Outlook: pursuing expansion opportunities and potential revenue-generation avenues.

Governance, risk & internal controls

• Internal audit by Dikshant Singh Panwar; reports to Audit Committee.
• Independent Directors held meeting as required; no material governance issues.
• Related party transactions are in the ordinary course; none disclosed as material.
• Risk management framework in place; regulatory & currency risks monitored.

AGM, disclosures & regulatory

• 39th AGM scheduled for 23 September 2026 via VC/OAVM.
• Remote e-voting window: 20-22 September 2026; voting at AGM possible for VC attendees.
• Notice/electronic Annual Report; physical copies on request; no proxy form due to VC/OAVM.
• CEO/CFO certification submitted; directors declared non-disqualification.

AGM details

• AGM date/time and mode: VC/OAVM as per notice.
• Record/book closure dates mentioned in the notice.

Resolutions proposed

• Ordinary: Adopt audited financial statements for the year.
• Ordinary: Re-appoint director by rotation.
• Special: Change designation to Managing Director; terms and remuneration as annexed.
• Special: Regularize additional Independent Director as Director.
• Special: Regularize another additional Independent Director as Director.
• Special: Appoint Statutory Auditors; fix remuneration.
• Ordinary: Increase Authorized Share Capital and MOA alteration.
• Special: Regularize additional Non-Independent Director as Director.
• Special: Regularize additional Director as Director.

Director changes

• Resignations: multiple directors resigned in prior year.
• Appointments: Executive Director appointed with concurrent CFO appointment.
• Secretarial/appointment: Company Secretary appointed.

Auditor appointments

• Statutory auditors appointed; tenure five years.
• Remuneration to be fixed by the Board.

Related party transactions

• No material related party transactions disclosed.

Book closure details

• Equity shares: book closure from 17/09/2026 to 23/09/2026, both days inclusive.
• Purpose: for the 39th AGM to be held on 23 September 2026.
• AGM date: 23 September 2026.
• Security: Equity shares (BACPHAR).
• E-voting: period not provided.
• Dividend: no dividend declared for FY 2025-26.

AGM & Financial Reporting

• Board approved the 39th AGM notice for Sept 23, 2026 at 3:00 PM via VC/OAVM.
• Directors' Report for FY ended March 31, 2026 approved.
• AGM to receive audited standalone financial statements for FY 2025-26.

Leadership & MD designation

• Change designation of Chaitali Kalpataru Shah from Executive Director to Managing Director, effective 25 Aug 2026.
• Tenure until 28 July 2029; remuneration as per notice within Schedule V.
• MD will retire by rotation.
• Board authorized to revise terms/remuneration within applicable laws.

Directors & Independent Directors

• Omprakash Pyarelal Sonar Regularization as Director (Independent) at AGM.
• Vivek Mukesh Yadav Regularization as Independent Director.
• Mahesh Singh Regularization as Independent Director.
• Anil Singh Regularization as Non-Executive Director.
• All appointments to be via ordinary/special resolutions at AGM.

Capital Structure & MOA

• Increase Authorized Share Capital from Rs 20 crore to Rs 70 crore.
• Alter MOA Clause V to reflect new capital.

Auditors

• Appoint Sarang Shivajirao Chavan & Associates as statutory auditors from AGM until 43rd AGM.
• Remuneration to be decided by the Board.

Regulatory & Compliance Notes

• AGM through VC/OAVM per MCA/SEBI guidelines; physical attendance dispensed.

Meeting Details

• Board meeting scheduled for 29 August 2026; time and venue not disclosed.

Key Agenda Items

• Discussion on Notice for 39th AGM of the Company.
• Discussion on Approval of Director Report for FY 2025-2026.
• Discussion to Fix Date, Place and Timing of 39th AGM.

Other Notes

• Trading window closure periods not specified.

Directors appointed

• Mr. Mahesh Singh appointed as Additional Independent Director, effective 25 August 2026, subject to member approval.
• Mr. Anil Shiv Charan Singh appointed as Additional Non-Executive Director, effective 25 August 2026, subject to member approval.
• Directors submitted declarations; not debarred by SEBI or regulator.